Infant Bacterial Therapeutics (IBT) is a pharmaceutical company dedicated to developing and marketing drugs that target diseases affecting prematurely born infants or caused by antibiotic-resistant bacteria. Their flagship drug candidate is IBP-9414, which aims to reduce the incidence of necrotizing enterocolitis (NEC) and improve sustained feeding tolerance (SFT) in prematurely born infants. This drug contains Lactobacillus reuteri, a bacterial strain found naturally in human breast milk.

Currently, IBP-9414 is in a pivotal Phase III study for registration approval. In addition to IBP-9414, IBT also has a portfolio of other drug candidates, including IBP-1016 for gastroschisis, IBP-1118 for retinopathy of prematurity (ROP), and IBP-1122 for vancomycin-resistant enterococci (VRE) infections. By developing these drugs, IBT aims to address medical needs that currently lack effective treatments.

IBT was founded in 2013 as a subsidiary of BioGaia, with a specific focus on developing drugs for premature infants. Since then, the company has made significant progress in clinical studies and received positive opinions from regulatory bodies like the European Medicines Agency (EMA). With a strong commitment to improving infant healthcare, IBT is poised to make a significant impact in the field of pediatric medicine